SunJu Chae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
SunJu Chae has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Dong-Hyun Kim
Neurobiota Research Center, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea
1 shared publication - Eun-Ha Joh
Department of Life and Nanopharmaceutical Sciences and Department of Pharmaceutical Science, Kyung Hee University, 1, Hoegi, Dongdaemun-Ku, Seoul, 130-701, Republic of Korea
1 shared publication - In-Ah Lee
Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, 1, Hoegi, Dongdaemun-Ku, Seoul 130-701, Korea
1 shared publication - Sang-Jun Han
Department of Life and Nanopharmaceutical Sciences and Department of Pharmaceutical Science, Kyung Hee University, Seoul, Republic of Korea
1 shared publication
Latest Publications
- 3 December 2009
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 25 (5) , 545-551
Lancemaside A ameliorates colitis by inhibiting NF-κB activation in TNBS-induced colitis mice
Purpose In a preliminary study, we found that lancemaside A, which is a main constituent of Codonopsis lanceolata used as an herbal medicine for inflammatory diseases, potently inhibits lipopolysaccharide (LPS)-stimulated, TLR-4-linked NF-κB activation of NF-κB luciferase reporter gene-transfected 293-hTLR4-hemagglutinin (HA) cells. Therefore, we investigated its inhibitory effect in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in mice. Methods We measured the ability of lancemaside A to inhibit LPS-stimulated, TLR-4-linked NF-κB activation in human embryonic kidney (HEK) cells, as well as to inhibit colitis outcomes in TNBS-induced colitis in mice. We also measured levels of the inflammatory markers, interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-6, and their transcription factor, NF-κB, in intestinal mucosa by enzyme-linked immunosorbent assay and immunoblotting. Result Intrarectal treatment of TNBS in mice caused colon shortening and also increased colonic expression of IL-1β, IL-6, and TNF-α expression. Oral administration of lancemaside A (10 and 20 mg/kg), inhibited colon shortening and myeloperoxidase activity in TNBS-induced colitic mice and also decreased colonic expression of IL-1β, IL-6, and TNF-α. Lancemaside A inhibited NF-κB activation induced by TNBS, as well as the expression of cyclooxygenase 2 and TLR-4. Lancemaside A also reduced the activity of intestinal bacterial β-glucuronidase that was induced by TNBS. Conclusions Lancemaside A ameliorates colitis via inhibition of TLR-4-linked NF-κB activation.
- 3 December 2009
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 25 (5) , 545-551
Lancemaside A ameliorates colitis by inhibiting NF-κB activation in TNBS-induced colitis mice
Purpose In a preliminary study, we found that lancemaside A, which is a main constituent of Codonopsis lanceolata used as an herbal medicine for inflammatory diseases, potently inhibits lipopolysaccharide (LPS)-stimulated, TLR-4-linked NF-κB activation of NF-κB luciferase reporter gene-transfected 293-hTLR4-hemagglutinin (HA) cells. Therefore, we investigated its inhibitory effect in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in mice. Methods We measured the ability of lancemaside A to inhibit LPS-stimulated, TLR-4-linked NF-κB activation in human embryonic kidney (HEK) cells, as well as to inhibit colitis outcomes in TNBS-induced colitis in mice. We also measured levels of the inflammatory markers, interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-6, and their transcription factor, NF-κB, in intestinal mucosa by enzyme-linked immunosorbent assay and immunoblotting. Result Intrarectal treatment of TNBS in mice caused colon shortening and also increased colonic expression of IL-1β, IL-6, and TNF-α expression. Oral administration of lancemaside A (10 and 20 mg/kg), inhibited colon shortening and myeloperoxidase activity in TNBS-induced colitic mice and also decreased colonic expression of IL-1β, IL-6, and TNF-α. Lancemaside A inhibited NF-κB activation induced by TNBS, as well as the expression of cyclooxygenase 2 and TLR-4. Lancemaside A also reduced the activity of intestinal bacterial β-glucuronidase that was induced by TNBS. Conclusions Lancemaside A ameliorates colitis via inhibition of TLR-4-linked NF-κB activation.